May 17, 2020 – A new study sought to reveal whether drug-eluting stents (DES) coated with bioabsorbable polymer (BP) presented a safety advantage without compromising efficacy compared to durable...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
-
-
Roxana Mehran, M.D., FACC, FACP, FCCP, FESC, FAHA, FSCAI, professor of medicine and director of interventional...
-
Ajay J. Kirtane, M.D., associate professor of medicine at Columbia University Irving Medical Center and director of the cardiac catheterization laboratories at NewYork-Presbyterian (NYP) Hospital...
-
Roxana Mehran, M.D., FACC, FACP, FCCP, FESC, FAHA, FSCAI, professor of medicine and director of...
The Boston Scientific Synergy stent uses a unique abluminal, bioresorbable drug-carrier polymer that dissolves after the vessel wall has healed months after the stent is implanted. Stent polymers have been implicated in cases of late-stent thrombosis, which required patients with DES to stay on dual antiplatelet therapy (DAPT). This study looked at using the device as a way to shorten DAPT duration.
News | Stents | May 17, 2020
May 17, 2020 – A new study sought to reveal whether drug-eluting stents (DES) coated with bioabsorbable polymer (BP)...
News | Stents | February 24, 2020
February 24, 2020 — Biotronik announced three-year data from the BIOFLOW-V Trial, which was presented yesterday at the...
The Boston Scientific Eluvia self-expanding, drug-eluting, peripheral stent.
Feature | Stents | February 11, 2020 | Saloni Walimbe
Cardiovascular diseases (CVDs) are among the leading causes of death across the globe. For patients suffering from high...
The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) were evaluated to determine if there is an increased mortality risk due to paclitaxel, but was no difference was seen in the five-year mortality rates compared to control patients.
Feature | Stents Peripheral | November 06, 2019 | Dave Fornell, Editor
November 6, 2019 – The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES)...
News | Peripheral Artery Disease (PAD) | November 06, 2019
November 6, 2019 – Boston Scientific announced positive data for two of its devices within the peripheral drug-eluting...
EchoPixel showed technology at TCT 2019 that creates live holograms in the cath lab from 3-D TEE imaging. It projects the holograms on a special display screen that does not require the user to wear 3-D glasses. The interventional cardiologist can use hand movements and a foot switch to move the image around without breaking the sterile field. It offers a new way to visualize catheters, device positioning and deployment in structural heart procedures. (Photos by Dave Fornell)
Feature | TCT | November 04, 2019 | Dave Fornell, Editor
The latest in interventional cardiology clinical data and new device technologies were highlighted at the annual...
Videos | Antiplatelet and Anticoagulation Therapies | October 17, 2019
Roxana Mehran, M.D., FACC, FACP, FCCP, FESC, FAHA, FSCAI, professor of medicine and director of interventional...
News | Stents Drug Eluting | October 11, 2019
October 11, 2019 — The ultra-thin Supraflex drug-eluting stent (DES) from SMT maintained numerically lower outcomes at...
Videos | Antiplatelet and Anticoagulation Therapies | October 11, 2019
Ajay J. Kirtane, M.D., associate professor of medicine at Columbia University Irving Medical Center and director of the...
Videos | Antiplatelet and Anticoagulation Therapies | October 10, 2019
Roxana Mehran, M.D., FACC, FACP, FCCP, FESC, FAHA, FSCAI, professor of medicine and director of interventional...
Videos | Antiplatelet and Anticoagulation Therapies | October 08, 2019
American Heart Association President Robert Harrington, M.D., interventional cardiologist and the Arthur L. Bloomfield...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.
Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with...
News | Stents Drug Eluting | September 30, 2019
September 30, 2019 – The first randomized trial to compare a durable polymer drug-eluting stent to a polymer-free drug-...
News | Stents Drug Eluting | September 30, 2019
September 30, 2019 — A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual...
News | Cath Lab | September 25, 2019
September 25, 2019 — Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting...
